Legg-Calvé-Perthes DiseaseWOMACNCT02795494
WOMAC Hip Score in Children and Adolescents With Perthes Disease
An observational study of Legg-Calvé-Perthes Disease, run by British Columbia Children's Hospital at 1 site in Canada.
Trial summary
Patient oriented clinical outcomes have increased in use and popularity and provide a comprehensive assessment of the level of symptoms and function experienced by a patient. Though several measures have been developed and shown to be valid, reliable, and responsive in adults, such efforts have only been rarely… Read more about this study
- Who is it for?
- Ages 5 to 19 yearsHealthy volunteers can take part
- Conditions the study is for
- Legg-Calvé-Perthes Disease
- What is being tested?
- WOMAC questionnaire at baseline, ASK-P questionnaire at baseline and WOMAC questionnaire at 2 weeks
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 200 participants
- Where
- 1 siteCanada
- Study dates
- May 2007to May 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 19 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: All children and adolescents, between the ages of five and nineteen years, being followed at the Orthopaedic clinic of a participating center with a diagnosis of an upper extremity fracture or healed Perthes disease will be eligible for inclusion in the study.
Who may be able to join
- All participants will be between 5-19 years
- Healed Perthes disease. Healed Perthes disease will be defined radiographically, in the accepted fashion, by the appearance of normal bone density of the femoral head. The restriction of those with Perthes disease to only those with resolution of the disease will prevent heterogeneity of the clinical presentation and anticipated functional abilities which would occur by including those in the acute phases of the disease, thereby reducing potential bias.
- All participants will have to be able to complete the questionnaires in English and, for those with Perthes disease, be able to complete the questionnaires again two weeks following the initial completion.
Who cannot join
- Amongst those being followed at the orthopaedic clinic of a participating center with an upper extremity fracture, those with a history of a hip disorder will be excluded. The reason for this is that these subjects will compose a comparison group with normal hip function, consequently a history of hip disorder would bias this comparison.
- Those with Perthes disease who demonstrate acute phases of the disease will be excluded. Acute phases of the disease will be defined in the accepted fashion, by the radiographic presence of fragmentation or reossification of the femoral head.
- Those who do not provide consent for participation in the study will be excluded, as will those who either cannot complete the questionnaire in English or are unable to complete a second set of questionnaires at two weeks.
- Those with cognitive impairment, precluding completion of the questionnaires, will be excluded.
- All those with concomitant medical problems will be excluded due to possible confounding of the clinical outcome measures.
Trial locations and contacts
1 site in 1 country.
Canada1 site, 1 recruiting
- Recruiting
British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4
Kishore Mulpuri, MBBS, MS(Ortho), MHSc, 604-875-2054, kmulpuri@cw.bc.ca
About this study
Official title: Validation and Reliability Testing of the Western Ontario and McMaster Osteoarthritis Scale (WOMAC) Hip Score in Children and Adolescents With Perthes Disease
Patient oriented clinical outcomes have increased in use and popularity and provide a comprehensive assessment of the level of symptoms and function experienced by a patient. Though several measures have been developed and shown to be valid, reliable, and responsive in adults, such efforts have only been rarely undertaken in pediatric populations. Specifically, there has been no validation of the predominant adult hip specific outcome measures, such as the WOMAC and Oxford-12, in children and adolescents. Prior to using such measures in pediatric patients, it is necessary to establish the psychometric properties of these measurements in this population.
The objective of this study is to determine the reliability and validity of the WOMAC hip scores in a pediatric population, between five and nineteen years of age, with Perthes disease. The results of this study will accomplish the above goal, thereby allowing either for widespread use of these measures in pediatric hip disorders or emphasizing the necessity for development of a pediatric hip specific outcome measure.
Read the detailed description
- Purpose Perthes disease is a hip disorder most often affecting children with an onset between four and eight years of age. The treatment options range from non-operative to bracing to operative intervention. As the disease most often affects the head of the femur, there is the potential for long-term conditions due to the residual hip joint deformity, following resolution of Perthes disease, leading to early degenerative hip osteoarthritis and potential impact on hip function, quality of life, and morbidity. A valid and reliable means by which to assess function and outcome is essential to determine the most effective means of treatment. Previous research has used different methods in different subject groups, making comparisons of results very difficult. Both the long-term outcome and change over time of a patient with Perthes disease could be measured with a hip joint specific patient oriented outcome measure. Several such measures have been developed in adults; specifically the Western Ontario and McMaster Osteoarthritis Scale (WOMAC) hip score are used very often. Though these tools have been well studied and validated in adults, they have not been tested or used in pediatric populations. As they were developed and shown to be valid, reliable, and responsive in adults, these measures require rigourous testing in pediatric populations prior to their use.
- Hypothesis There is no true global hypothesis for the study since it is a validation/reliability study. There are hypotheses for each type of validity being studied. For construct validity (using convergence), the hypothesis would be a priori hypothesis in this study related to convergent validity is that, assuming the WOMAC has construct validity in this population, then the hip specific outcome scores should be different for each Stulberg classification stage. For construct validity (using extreme groups), the hypothesis would be a priori hypothesis in this study is that, assuming the measures have adequate construct validity in this population, the group of subjects being followed for treatment of an upper extremity fracture should have significantly better function, as indicated by a low score on the WOMAC and , compared to those with Perthes disease, who should have higher scores indicating poorer function. For criterion validity, the hypothesis would be a priori hypothesis related to criterion validity in this study predicts that, assuming adequate concurrent validity of these measures in this population, there should be a negative correlation between the Activities Scale for Kids - Performance (ASK-p, an activity level outcome score) and the WOMAC. The reason for a negative correlation is that high scores on the generic measure indicate better function, whereas low scores on the hip specific measures indicate better function.
- Research Method All subjects enrolled in the study will be given the initial set of questionnaires at the time of recruitment and asked to complete them at home, following the clinical follow-up visit, and return the questionnaires by mail using a self-addressed, stamped envelope which will be provided. All subjects will complete the WOMAC. Those with healed Perthes disease will also complete the ASK-p at the first visit to the clinic following consent into the study. Those in the comparison group with an upper extremity fracture will not complete the generic measure. This will comprise the initial time point of the study. Those subjects who do not complete all required questionnaires, at this time point, will be excluded from the study. Radiographs of the affected hip and pelvis will be obtained for each patient with healed Perthes disease at the time of the clinic visit, which would be obtained regardless of inclusion in the study in the course of standard clinical follow-up. Those subjects with Perthes disease will also complete the WOMAC and measure two weeks following the initial time point. The questionnaires will be mailed to the subjects and they will be asked to complete the questionnaires and return them in a self-addressed, stamped envelope which will be provided. This will comprise the follow-up time point of the study. A reminder notification will be mailed at four weeks and a telephone call reminder at six weeks following the initial time point if the second series of questionnaires has not been returned. Those who do not complete the second series of questionnaires will be excluded from the reliability component of the study but maintained in the validity phase, provided the initial questionnaires were completed. Those with an upper-extremity fracture will not complete any additional questionnaires following the initial time point. The Stulberg classification will be determined, as outlined, following the initial time point but prior to analysis of the data.
- Statistical Analysis All statistical analysis will be performed by a blinded, independent analyst. All analyses, with the exception of the weighted kappa statistic which will be calculated manually, will be performed with the use of S-PLUS software (version 6.2, Lucent Technologies, Inc.). The distribution of all questionnaire data will be determined with the use of frequency histograms to allow for the use of appropriate statistical tests. All statistical tests will be performed with α=0.05. The reported values will be the mean and the corresponding 95% confidence interval. Where two groups are compared, the mean difference between the groups and the 95% confidence interval of the difference will be reported.
There have been no previous studies or data of the WOMAC in a pediatric population. Using values obtained in studies of adults may not provide a good estimate for a power analysis in this population since other outcome measures, which have been validated in adults, have been shown to lack validity in children and adolescents. However, in order to estimate the sample size required for the correlation between the ASK-p and the hip outcome measures the previously reported adult derived values were required. On the basis of a minimum correlation of 0.6, which would be considered adequate, with α=0.05 and 80 per cent power, a total of 40 children are required for the study. Since there is no available evidence with which to estimate the correlation between these outcome measures, a liberal sample size will be recruited. In a similar study, except that generic as opposed to joint specific, outcome measures were used, a sample size of 196 subjects was recruited. Young et al recruited 200 subjects for their study in which several psychometric properties of the ASK-p were determined. A total of 200 subjects will be recruited across all centers participating in this study. There will be 100 subjects with an upper extremity fracture and 100 with healed Perthes disease. This sample size was chosen, in part, on the basis of the maximum number of subjects with healed Perthes which would be feasible to recruit over the time horizon of the study, which will be six months. It is anticipated that a minimum of four centers will participate in the study.
- Conditions
- Legg-Calvé-Perthes Disease
- Being tested
- WOMAC questionnaire at baseline, ASK-P questionnaire at baseline, WOMAC questionnaire at 2 weeks
- Medical subject headings
- Legg-Calve-Perthes Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WOMAC questionnaire at baselineBehavioural
Patient-reported pain, stiffness and physical function outcome score
ASK-P questionnaire at baselineBehavioural
Patient-reported activity level score
WOMAC questionnaire at 2 weeksBehavioural
Patient-reported pain, stiffness and physical function outcome score
| Study group | Role | What they receive |
|---|---|---|
| Perthes Group | Participants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline. Receives: Behavioral: WOMAC questionnaire at baseline; Behavioral: ASK-P questionnaire at baseline; Behavioral: WOMAC questionnaire at 2 weeks | |
| Fracture Control Group | Participants with an upper extremity fracture but no hip-related conditions. Will be given WOMAC questionnaire at baseline. Receives: Behavioral: WOMAC questionnaire at baseline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in WOMAC questionnaire scores between the five Stulberg classification stages in the Perthes group
Measured: Baseline
Secondary outcomes (3)
Difference in WOMAC questionnaire scores between baseline and 2 weeks
Measured: Baseline to two weeks
Difference in WOMAC questionnaire scores between the Perthes and control group
Measured: Baseline
Correlation between WOMAC questionnaire and ASK-P scores in the Perthes group
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2016 (estimated)
- Study startMay 2007
- Primary completionMay 2020 (estimated)
- Study completionMay 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Legg-Calvé-Perthes DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- British Columbia Children's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kishore Mulpuri, British Columbia Children's Hospital
- Investigators
- Kishore Mulpuri, MBBS, MS(Ortho), MHSc, Principal investigator, Provincial Health Services Authority British Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02795494
- Sponsor's protocol ID
- H0700752
- Acronym
- WOMAC
- Status last verified
- Jun 2016
- First submitted
- 26 May 2016
- Last updated
- 10 Jun 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Young NL, Williams JI, Yoshida KK, Wright JG. Measurement properties of the activities scale for kids. J Clin Epidemiol. 2000 Feb;53(2):125-37. doi: 10.1016/s0895-4356(99)00113-4.
PubMed 10729684
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation and Reliability Testing of the Western Ontario and McMaster Osteoarthritis Scale (WOMAC) Hip Score in Children and Adolescents With Perthes Disease
- ClinicalTrials.gov ID
- NCT02795494
- Acronym / sponsor ID
- WOMAC / H0700752
- Conditions
- Legg-Calvé-Perthes Disease
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- British Columbia Children's HospitalUniversity, hospital or other
- Study start
- May 2007
- Primary completion
- May 2020 (estimated)
- Study completion
- May 2020 (estimated)
- First posted
- 10 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patient oriented clinical outcomes have increased in use and popularity and provide a comprehensive assessment of the level of symptoms and function experienced by a patient. Though several measures have been developed and shown to be valid, reliable, and responsive in adults, such efforts have only been rarely undertaken in pediatric populations. Specifically, there has been no validation of the predominant adult hip specific outcome measures, such as the WOMAC and Oxford-12, in children and adolescents. Prior to using such measures in pediatric patients, it is necessary to establish the psychometric properties of these measurements in this population.
The objective of this study is to determine the reliability and validity of the WOMAC hip scores in a pediatric population, between five and nineteen years of age, with Perthes disease. The results of this study will accomplish the above goal, thereby allowing either for widespread use of these measures in pediatric hip disorders or emphasizing the necessity for development of a pediatric hip specific outcome measure.
Detailed description
- Purpose Perthes disease is a hip disorder most often affecting children with an onset between four and eight years of age. The treatment options range from non-operative to bracing to operative intervention. As the disease most often affects the head of the femur, there is the potential for long-term conditions due to the residual hip joint deformity, following resolution of Perthes disease, leading to early degenerative hip osteoarthritis and potential impact on hip function, quality of life, and morbidity. A valid and reliable means by which to assess function and outcome is essential to determine the most effective means of treatment. Previous research has used different methods in different subject groups, making comparisons of results very difficult. Both the long-term outcome and change over time of a patient with Perthes disease could be measured with a hip joint specific patient oriented outcome measure. Several such measures have been developed in adults; specifically the Western Ontario and McMaster Osteoarthritis Scale (WOMAC) hip score are used very often. Though these tools have been well studied and validated in adults, they have not been tested or used in pediatric populations. As they were developed and shown to be valid, reliable, and responsive in adults, these measures require rigourous testing in pediatric populations prior to their use.
- Hypothesis There is no true global hypothesis for the study since it is a validation/reliability study. There are hypotheses for each type of validity being studied. For construct validity (using convergence), the hypothesis would be a priori hypothesis in this study related to convergent validity is that, assuming the WOMAC has construct validity in this population, then the hip specific outcome scores should be different for each Stulberg classification stage. For construct validity (using extreme groups), the hypothesis would be a priori hypothesis in this study is that, assuming the measures have adequate construct validity in this population, the group of subjects being followed for treatment of an upper extremity fracture should have significantly better function, as indicated by a low score on the WOMAC and , compared to those with Perthes disease, who should have higher scores indicating poorer function. For criterion validity, the hypothesis would be a priori hypothesis related to criterion validity in this study predicts that, assuming adequate concurrent validity of these measures in this population, there should be a negative correlation between the Activities Scale for Kids - Performance (ASK-p, an activity level outcome score) and the WOMAC. The reason for a negative correlation is that high scores on the generic measure indicate better function, whereas low scores on the hip specific measures indicate better function.
- Research Method All subjects enrolled in the study will be given the initial set of questionnaires at the time of recruitment and asked to complete them at home, following the clinical follow-up visit, and return the questionnaires by mail using a self-addressed, stamped envelope which will be provided. All subjects will complete the WOMAC. Those with healed Perthes disease will also complete the ASK-p at the first visit to the clinic following consent into the study. Those in the comparison group with an upper extremity fracture will not complete the generic measure. This will comprise the initial time point of the study. Those subjects who do not complete all required questionnaires, at this time point, will be excluded from the study. Radiographs of the affected hip and pelvis will be obtained for each patient with healed Perthes disease at the time of the clinic visit, which would be obtained regardless of inclusion in the study in the course of standard clinical follow-up. Those subjects with Perthes disease will also complete the WOMAC and measure two weeks following the initial time point. The questionnaires will be mailed to the subjects and they will be asked to complete the questionnaires and return them in a self-addressed, stamped envelope which will be provided. This will comprise the follow-up time point of the study. A reminder notification will be mailed at four weeks and a telephone call reminder at six weeks following the initial time point if the second series of questionnaires has not been returned. Those who do not complete the second series of questionnaires will be excluded from the reliability component of the study but maintained in the validity phase, provided the initial questionnaires were completed. Those with an upper-extremity fracture will not complete any additional questionnaires following the initial time point. The Stulberg classification will be determined, as outlined, following the initial time point but prior to analysis of the data.
- Statistical Analysis All statistical analysis will be performed by a blinded, independent analyst. All analyses, with the exception of the weighted kappa statistic which will be calculated manually, will be performed with the use of S-PLUS software (version 6.2, Lucent Technologies, Inc.). The distribution of all questionnaire data will be determined with the use of frequency histograms to allow for the use of appropriate statistical tests. All statistical tests will be performed with α=0.05. The reported values will be the mean and the corresponding 95% confidence interval. Where two groups are compared, the mean difference between the groups and the 95% confidence interval of the difference will be reported.
There have been no previous studies or data of the WOMAC in a pediatric population. Using values obtained in studies of adults may not provide a good estimate for a power analysis in this population since other outcome measures, which have been validated in adults, have been shown to lack validity in children and adolescents. However, in order to estimate the sample size required for the correlation between the ASK-p and the hip outcome measures the previously reported adult derived values were required. On the basis of a minimum correlation of 0.6, which would be considered adequate, with α=0.05 and 80 per cent power, a total of 40 children are required for the study. Since there is no available evidence with which to estimate the correlation between these outcome measures, a liberal sample size will be recruited. In a similar study, except that generic as opposed to joint specific, outcome measures were used, a sample size of 196 subjects was recruited. Young et al recruited 200 subjects for their study in which several psychometric properties of the ASK-p were determined. A total of 200 subjects will be recruited across all centers participating in this study. There will be 100 subjects with an upper extremity fracture and 100 with healed Perthes disease. This sample size was chosen, in part, on the basis of the maximum number of subjects with healed Perthes which would be feasible to recruit over the time horizon of the study, which will be six months. It is anticipated that a minimum of four centers will participate in the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Perthes Group | – | Behavioral: WOMAC questionnaire at baseline, Behavioral: ASK-P questionnaire at baseline, Behavioral: WOMAC questionnaire at 2 weeksParticipants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline. |
| Fracture Control Group | – | Behavioral: WOMAC questionnaire at baselineParticipants with an upper extremity fracture but no hip-related conditions. Will be given WOMAC questionnaire at baseline. |
Who may qualify
- Ages
- 5 to 19 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- All children and adolescents, between the ages of five and nineteen years, being followed at the Orthopaedic clinic of a participating center with a diagnosis of an upper extremity fracture or healed Perthes disease will be eligible for inclusion in the study.
Key inclusion criteria (3 listed)
- All participants will be between 5-19 years
- Healed Perthes disease. Healed Perthes disease will be defined radiographically, in the accepted fashion, by the appearance of normal bone density of the femoral head. The restriction of those with Perthes disease to only those with resolution of the disease will prevent heterogeneity of the clinical presentation and anticipated functional abilities which would occur by including those in the acute phases of the disease, thereby reducing potential bias.
- All participants will have to be able to complete the questionnaires in English and, for those with Perthes disease, be able to complete the questionnaires again two weeks following the initial completion.
Key exclusion criteria (5 listed)
- Amongst those being followed at the orthopaedic clinic of a participating center with an upper extremity fracture, those with a history of a hip disorder will be excluded. The reason for this is that these subjects will compose a comparison group with normal hip function, consequently a history of hip disorder would bias this comparison.
- Those with Perthes disease who demonstrate acute phases of the disease will be excluded. Acute phases of the disease will be defined in the accepted fashion, by the radiographic presence of fragmentation or reossification of the femoral head.
- Those who do not provide consent for participation in the study will be excluded, as will those who either cannot complete the questionnaire in English or are unable to complete a second set of questionnaires at two weeks.
- Those with cognitive impairment, precluding completion of the questionnaires, will be excluded.
- All those with concomitant medical problems will be excluded due to possible confounding of the clinical outcome measures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WOMAC questionnaire at baselinePatient-reported pain, stiffness and physical function outcome score | Behavioural | Fracture Control Group, Perthes Group |
| ASK-P questionnaire at baselinePatient-reported activity level score | Behavioural | Perthes Group |
| WOMAC questionnaire at 2 weeksPatient-reported pain, stiffness and physical function outcome score | Behavioural | Perthes Group |
Primary outcome
Difference in WOMAC questionnaire scores between the five Stulberg classification stages in the Perthes group
Time frame: Baseline
3 secondary outcomes
Difference in WOMAC questionnaire scores between baseline and 2 weeks
Time frame: Baseline to two weeks
Difference in WOMAC questionnaire scores between the Perthes and control group
Time frame: Baseline
Correlation between WOMAC questionnaire and ASK-P scores in the Perthes group
Time frame: Baseline
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2016.
- Background: PubMed 10729684Young NL, Williams JI, Yoshida KK, Wright JG. Measurement properties of the activities scale for kids. J Clin Epidemiol. 2000 Feb;53(2):125-37. doi: 10.1016/s0895-4356(99)00113-4.
- Individual participant dataSharing planned: No
Related trials for Legg-Calvé-Perthes Disease
Recruiting
Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis
Osteonecrosis of the Femoral Head, Avascular Necrosis of the Femoral Head
Active, not recruiting
Early Feasibility Study of Cartilage Defect Repair
Osteoarthritis, Hip, Femoroacetabular Impingement
RecruitingPhase 2
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Sickle Cell Disease, Sickle Cell Anemia
RecruitingObservational study
Screening for Biomarkers of Osteonecrosis of the Femoral Head
Osteonecrosis of the Femoral Head
Active, not recruitingObservational study
Mixed-Methods Evaluation of Short-, Medium-, and Long-Term Outcomes Following Hip Treatment
Hip Dysplasia, Legg-Calvâe-Perthes Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kishore Mulpuri, MBBS, MS(Ortho), MHSc principal investigator
Provincial Health Services Authority British Columbia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Legg-Calvé-Perthes Disease, run by British Columbia Children's Hospital at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Kishore Mulpuri, MBBS, MS(Ortho), MHSc (604-875-2054, kmulpuri@cw.bc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in WOMAC questionnaire scores between the five Stulberg classification stages in the Perthes group (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02795494, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2016.